Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction
|
摘要
Pancreatic ductal adenocarcinoma(PDAC) has the poorest prognosis of all malignancies and is largely resistant to standard therapy. Novel treatments against PDAC are desperately needed. Anti-Gal is the most abundant natural antibody in humans,comprising about 1% of immunoglobulins and is also naturally produced in apes and Old World monkeys. The anti-Gal ligand is a carbohydrate antigen called "α-gal epitopes" with the structure Galα1-3Galβ1-4Glc NAc-R. These epitopes are expressed as major carbohydrate antigens in non-primate mammals,prosimians,and New World monkeys. Anti-Gal is exploited in cancer vaccines to increase the immunogenicity of antigen-presenting cells(APCs). Cancer cells or PDAC tumor lysates are processed to express α-gal epitopes. Vaccination with these components results in in vivo opsonization by anti-Gal Ig G in PDAC patients. The Fc portion of the vaccine-bound anti-Gal interacts with Fcγ receptors of APCs,inducing uptake of the vaccine components,transport of the vaccine tumor membranes to draining lymph nodes,and processing and presentation of tumor-associated antigens(TAAs). Cancer vaccines expressing α-gal epitopes elicit strong antibody production against multiple TAAs contained in PDAC cells and induce activation of multiple tumor-specific T cells. Here,we review new areas of clinical importance related to the α-gal epitope/anti-Gal antibody reaction and the advantages in immunotherapy against PDAC.
Pancreatic ductal adenocarcinoma(PDAC) has the poorest prognosis of all malignancies and is largely resistant to standard therapy. Novel treatments against PDAC are desperately needed. Anti-Gal is the most abundant natural antibody in humans,comprising about 1% of immunoglobulins and is also naturally produced in apes and Old World monkeys. The anti-Gal ligand is a carbohydrate antigen called "α-gal epitopes" with the structure Galα1-3Galβ1-4Glc NAc-R. These epitopes are expressed as major carbohydrate antigens in non-primate mammals,prosimians,and New World monkeys. Anti-Gal is exploited in cancer vaccines to increase the immunogenicity of antigen-presenting cells(APCs). Cancer cells or PDAC tumor lysates are processed to express α-gal epitopes. Vaccination with these components results in in vivo opsonization by anti-Gal Ig G in PDAC patients. The Fc portion of the vaccine-bound anti-Gal interacts with Fcγ receptors of APCs,inducing uptake of the vaccine components,transport of the vaccine tumor membranes to draining lymph nodes,and processing and presentation of tumor-associated antigens(TAAs). Cancer vaccines expressing α-gal epitopes elicit strong antibody production against multiple TAAs contained in PDAC cells and induce activation of multiple tumor-specific T cells. Here,we review new areas of clinical importance related to the α-gal epitope/anti-Gal antibody reaction and the advantages in immunotherapy against PDAC.
Pancreatic ductal adenocarcinoma(PDAC) has the poorest prognosis of all malignancies and is largely resistant to standard therapy. Novel treatments against PDAC are desperately needed. Anti-Gal is the most abundant natural antibody in humans,comprising about 1% of immunoglobulins and is also naturally produced in apes and Old World monkeys. The anti-Gal ligand is a carbohydrate antigen called "α-gal epitopes" with the structure Galα1-3Galβ1-4Glc NAc-R. These epitopes are expressed as major carbohydrate antigens in non-primate mammals,prosimians,and New World monkeys. Anti-Gal is exploited in cancer vaccines to increase the immunogenicity of antigen-presenting cells(APCs). Cancer cells or PDAC tumor lysates are processed to express α-gal epitopes. Vaccination with these components results in in vivo opsonization by anti-Gal Ig G in PDAC patients. The Fc portion of the vaccine-bound anti-Gal interacts with Fcγ receptors of APCs,inducing uptake of the vaccine components,transport of the vaccine tumor membranes to draining lymph nodes,and processing and presentation of tumor-associated antigens(TAAs). Cancer vaccines expressing α-gal epitopes elicit strong antibody production against multiple TAAs contained in PDAC cells and induce activation of multiple tumor-specific T cells. Here,we review new areas of clinical importance related to the α-gal epitope/anti-Gal antibody reaction and the advantages in immunotherapy against PDAC.
引文
1 American Cancer Society.Cancer Facts&Figures 2012.Atlanta:American Cancer Society,2012
2 Cress RD,Yin D,Clarke L,Bold R,Holly EA.Survival among patients with adenocarcinoma of the pancreas:a population-based study(United States).Cancer Causes Control 2006;17:403-409[PMID:16596292]
3 Winter JM,Cameron JL,Campbell KA,Arnold MA,Chang DC,Coleman J,Hodgin MB,Sauter PK,Hruban RH,Riall TS,Schulick RD,Choti MA,Lillemoe KD,Yeo CJ.1423pancreaticoduodenectomies for pancreatic cancer:A singleinstitution experience.J Gastrointest Surg 2006;10:1199-210;discussion 1210-1[PMID:17114007]
4 Garcea G,Dennison AR,Pattenden CJ,Neal CP,Sutton CD,Berry DP.Survival following curative resection for pancreatic ductal adenocarcinoma.A systematic review of the literature.JOP2008;9:99-132[PMID:18326920]
5 Roy R,Maraveyas A.Chemoradiation in pancreatic adenocarcinoma:a literature review.Oncologist 2010;15:259-269[PMID:20203172 DOI:10.1634/theoncologist.2009-0272]
6 Conroy T,Desseigne F,Ychou M,BouchéO,Guimbaud R,Bécouarn Y,Adenis A,Raoul JL,Gourgou-Bourgade S,de la Fouchardière C,Bennouna J,Bachet JB,Khemissa-Akouz F,Péré-VergéD,Delbaldo C,Assenat E,Chauffert B,Michel P,MontotoGrillot C,Ducreux M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med 2011;364:1817-1825[PMID:21561347 DOI:10.1056/NEJMoa1011923]
7 Oettle H,Post S,Neuhaus P,Gellert K,Langrehr J,Ridwelski K,Schramm H,Fahlke J,Zuelke C,Burkart C,Gutberlet K,Kettner E,Schmalenberg H,Weigang-Koehler K,Bechstein WO,Niedergethmann M,Schmidt-Wolf I,Roll L,Doerken B,Riess H.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:a randomized controlled trial.JAMA 2007;297:267-277[PMID:17227978]
8 Feig C,Gopinathan A,Neesse A,Chan DS,Cook N,Tuveson DA.The pancreas cancer microenvironment.Clin Cancer Res2012;18:4266-4276[PMID:22896693 DOI:10.1158/1078-0432.CCR-11-3114]
9 Mantovani A,Allavena P,Sica A,Balkwill F.Cancer-related inflammation.Nature 2008;454:436-444[PMID:18650914 DOI:10 .1038/nature07205]
10 Sideras K,Braat H,Kwekkeboom J,van Eijck CH,Peppelenbosch MP,Sleijfer S,Bruno M.Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.Cancer Treat Rev 2014;40:513-522[PMID:24315741 DOI:10 .1016/j.ctrv.2013.11.005]
11 Olive KP,Jacobetz MA,Davidson CJ,Gopinathan A,Mc Intyre D,Honess D,Madhu B,Goldgraben MA,Caldwell ME,Allard D,Frese KK,Denicola G,Feig C,Combs C,Winter SP,IrelandZecchini H,Reichelt S,Howat WJ,Chang A,Dhara M,Wang L,Rückert F,Grützmann R,Pilarsky C,Izeradjene K,Hingorani SR,Huang P,Davies SE,Plunkett W,Egorin M,Hruban RH,Whitebread N,Mc Govern K,Adams J,Iacobuzio-Donahue C,Griffiths J,Tuveson DA.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science 2009;324:1457-1461[PMID:19460966 DOI:10 .1126/science.1171362]
12 Galili U.Anti-Gal:an abundant human natural antibody of multiple pathogeneses and clinical benefits.Immunology 2013;140:1-11[PMID:23578170 DOI:10.1111/imm.12110]
13 Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin 2011;61:69-90[PMID:21296855 DOI:10.3322/caac.20107]
14 Bakkevold KE,Kambestad B.Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater--the prognostic factors influencing the long-term results.A prospective multicentre study.Eur J Surg Oncol 1993;19:147-161[PMID:7684003]
15 Riall TS,Cameron JL,Lillemoe KD,Winter JM,Campbell KA,Hruban RH,Chang D,Yeo CJ.Resected periampullary adenocarcinoma:5-year survivors and their 6-to 10-year followup.Surgery 2006;140:764-772[PMID:17084719]
16 Burris HA,Moore MJ,Andersen J,Green MR,Rothenberg ML,Modiano MR,Cripps MC,Portenoy RK,Storniolo AM,Tarassoff P,Nelson R,Dorr FA,Stephens CD,Von Hoff DD.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial.J Clin Oncol 1997;15:2403-2413[PMID:9196156]
17 Eguchi H,Nagano H,Tanemura M,Takeda Y,Marubashi S,Kobayashi S,Kawamoto K,Wada H,Hama N,Akita H,Mori M,Doki Y.Preoperative chemoradiotherapy,surgery and adjuvant therapy for resectable pancreatic cancer.Hepatogastroenterology2013;60:904-911[PMID:23321032 DOI:10.5754/hge12974]
18 Evans DB,Varadhachary GR,Crane CH,Sun CC,Lee JE,Pisters PW,Vauthey JN,Wang H,Cleary KR,Staerkel GA,Charnsangavej C,L a n o E A,H o L,L e n z i R,A b b r u z z e s e J L,Wo l ff R A.Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.J Clin Oncol2008;26:3496-3502[PMID:18640930 DOI:10.1200/JCO.2007]
19 Ohigashi H,Ishikawa O,Eguchi H,Takahashi H,Gotoh K,Yamada T,Yano M,Nakaizumi A,Uehara H,Tomita Y,Nishiyama K.Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine,concurrent three-dimensional conformal radiation,surgery,and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.Ann Surg 2009;250:88-95[PMID:19561477 DOI:10.1097/SLA.0b013e3181ad65cc]
20 Wedén S,Klemp M,Gladhaug IP,M?ller M,Eriksen JA,Gaudernack G,Buanes T.Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.Int J Cancer 2011;128:1120-1128[PMID:20473937 DOI:10 .1002/ijc.25449]
21 Shakhar G,Ben-Eliyahu S.Potential prophylactic measures against postoperative immunosuppression:could they reduce recurrence rates in oncological patients?Ann Surg Oncol 2003;10:972-992[PMID:14527919]
22 Weighardt H,Heidecke CD,Emmanuilidis K,Maier S,Bartels H,Siewert JR,Holzmann B.Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production.Surgery 2000;127:309-315[PMID:10715987]
23 Zou W.Immunosuppressive networks in the tumour environment and their therapeutic relevance.Nat Rev Cancer 2005;5:263-274[PMID:15776005]
24 Kraman M,Bambrough PJ,Arnold JN,Roberts EW,Magiera L,Jones JO,Gopinathan A,Tuveson DA,Fearon DT.Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.Science 2010;330:827-830[PMID:21051638 DOI:10.1126/science.1195300]
25 Erez N,Truitt M,Olson P,Arron ST,Hanahan D.CancerAssociated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappa BDependent Manner.Cancer Cell 2010;17:135-147[PMID:20138012 DOI:10.1016/j.ccr.2009.12.041]
26 Shi M,Yu DH,Chen Y,Zhao CY,Zhang J,Liu QH,Ni CR,Zhu MH.Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.World J Gastroenterol 2012;18:840-846[PMID:22371645 DOI:10 .3748/wjg.v18.i8.840]
27 Ostrand-Rosenberg S.Myeloid-derived suppressor cells:more mechanisms for inhibiting antitumor immunity.Cancer Immunol Immunother 2010;59:1593-1600[PMID:20414655 DOI:10 .1007/s00262-010-0855-8]
28 Gabitass RF,Annels NE,Stocken DD,Pandha HA,Middleton GW.Elevated myeloid-derived suppressor cells in pancreatic,esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.Cancer Immunol Immunother 2011;60:1419-1430[PMID:21644036 DOI:10.1007/s00262-011-1028-0]
29 Zhao F,Obermann S,von Wasielewski R,Haile L,Manns MP,Korangy F,Greten TF.Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.Immunology 2009;128:141-149[PMID:19689743 DOI:10.1111/j.1365-2567.2009.03105.x]
30 Esposito I,Menicagli M,Funel N,Bergmann F,Boggi U,Mosca F,Bevilacqua G,Campani D.Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma.J Clin Pathol 2004;57:630-636[PMID:15166270]
31 Kurahara H,Shinchi H,Mataki Y,Maemura K,Noma H,Kubo F,Sakoda M,Ueno S,Natsugoe S,Takao S.Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.J Surg Res 2011;167:e211-e219[PMID:19765725 DOI:10.1016/j.jss.2009.05.026]
32 Ikemoto T,Yamaguchi T,Morine Y,Imura S,Soejima Y,Fujii M,Maekawa Y,Yasutomo K,Shimada M.Clinical roles of increased populations of Foxp3+CD4+T cells in peripheral blood from advanced pancreatic cancer patients.Pancreas 2006;33:386-390[PMID:17079944]
33 Hiraoka N,Onozato K,Kosuge T,Hirohashi S.Prevalence of FOXP3+regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.Clin Cancer Res 2006;12:5423-5434[PMID:17000676]
34 Yamamoto T,Yanagimoto H,Satoi S,Toyokawa H,Hirooka S,Yamaki S,Yui R,Yamao J,Kim S,Kwon AH.Circulating CD4+CD25+regulatory T cells in patients with pancreatic cancer.Pancreas 2012;41:409-415[PMID:22158072 DOI:10.1097/MPA.0b013e3182373a66]
35 Galili U.The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.Immunol Cell Biol 2005;83:674-686[PMID:16266320]
36 Macher BA,Galili U.The Galalpha1,3Galbeta1,4Glc NAc-R(alpha-Gal)epitope:a carbohydrate of unique evolution and clinical relevance.Biochim Biophys Acta 2008;1780:75-88[PMID:18047841]
37 Kearns-Jonker M,Swensson J,Ghiuzeli C,Chu W,Osame Y,Starnes V,Cramer DV.The human antibody response to porcine xenoantigens is encoded by IGHV3-11 and IGHV3-74 Ig VH germline progenitors.J Immunol 1999;163:4399-4412[PMID:10510381]
38 Eto T,Ichikawa Y,Nishimura K,Ando S,Yamakawa T.Chemistry of lipid of the posthemyolytic residue or stroma of erythrocytes.XVI.Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes of rabbit.J Biochem 1968;64:205-213[PMID:4304380]
39 Stellner K,Saito H,Hakomori SI.Determination of aminosugar linkages in glycolipids by methylation.Aminosugar linkages of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen.Arch Biochem Biophys 1973;155:464-472[PMID:4735853]
40 Galili U.Discovery of the natural anti-Gal antibody and its past and future relevance to medicine.Xenotransplantation 2013;20:138-147[PMID:23577774 DOI:10.1111/xen.12034]
41 Tanemura M,Yin D,Chong AS,Galili U.Differential immune responses to alpha-gal epitopes on xenografts and allografts:implications for accommodation in xenotransplantation.J Clin Invest 2000;105:301-310[PMID:10675356]
42 Ekser B,Ezzelarab M,Hara H,van der Windt DJ,Wijkstrom M,Bottino R,Trucco M,Cooper DK.Clinical xenotransplantation:the next medical revolution?Lancet 2012;379:672-683[PMID:22019026 DOI:10.1016/S0140-6736(11)61091-X]
43 Tisato V,Cozzi E.Xenotransplantation:an overview of the field.Methods Mol Biol 2012;885:1-16[PMID:22565986 DOI:10.1007 /978-1-61779-845-0_1]
44 Groth CG,Korsgren O,Tibell A,Tollemar J,M?ller E,Bolinder J,Ostman J,Reinholt FP,Hellerstr?m C,Andersson A.Transplantation of porcine fetal pancreas to diabetic patients.Lancet 1994;344:1402-1404[PMID:7968077]
45 Lai L,Kolber-Simonds D,Park KW,Cheong HT,Greenstein JL,Im GS,Samuel M,Bonk A,Rieke A,Day BN,Murphy CN,Carter DB,Hawley RJ,Prather RS.Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.Science 2002;295:1089-1092[PMID:11778012]
46 Phelps CJ,Koike C,Vaught TD,Boone J,Wells KD,Chen SH,Ball S,Specht SM,Polejaeva IA,Monahan JA,Jobst PM,Sharma SB,Lamborn AE,Garst AS,Moore M,Demetris AJ,Rudert WA,Bottino R,Bertera S,Trucco M,Starzl TE,Dai Y,Ayares DL.Production of alpha 1,3-galactosyltransferase-deficient pigs.Science 2003;299:411-414[PMID:12493821]
47 Yamada K,Yazawa K,Shimizu A,Iwanaga T,Hisashi Y,Nuhn M,O’Malley P,Nobori S,Vagefi PA,Patience C,Fishman J,Cooper DK,Hawley RJ,Greenstein J,Schuurman HJ,Awwad M,Sykes M,Sachs DH.Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase geneknockout donors and the cotransplantation of vascularized thymic tissue.Nat Med 2005;11:32-34[PMID:15619627]
48 Kuwaki K,Tseng YL,Dor FJ,Shimizu A,Houser SL,Sanderson TM,Lancos CJ,Prabharasuth DD,Cheng J,Moran K,Hisashi Y,Mueller N,Yamada K,Greenstein JL,Hawley RJ,Patience C,Awwad M,Fishman JA,Robson SC,Schuurman HJ,Sachs DH,Cooper DK.Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors:initial experience.Nat Med 2005;11:29-31[PMID:15619628]
49 Saito H,Dubsky P,Dantin C,Finn OJ,Banchereau J,Palucka AK.Cross-priming of cyclin B1,MUC-1 and survivin-specific CD8+T cells by dendritic cells loaded with killed allogeneic breast cancer cells.Breast Cancer Res 2006;8:R65[PMID:17129372]
50 Thomas AM,Santarsiero LM,Lutz ER,Armstrong TD,Chen YC,Huang LQ,Laheru DA,Goggins M,Hruban RH,Jaffee EM.Mesothelin-specific CD8(+)T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.J Exp Med 2004;200:297-306[PMID:15289501]
51 Jaffee EM,Hruban RH,Biedrzycki B,Laheru D,Schepers K,Sauter PR,Goemann M,Coleman J,Grochow L,Donehower RC,Lillemoe KD,O’Reilly S,Abrams RA,Pardoll DM,Cameron JL,Yeo CJ.Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer:a phase I trial of safety and immune activation.J Clin Oncol 2001;19:145-156[PMID:11134207]
52 Acuto O,Michel F.CD28-mediated co-stimulation:a quantitative support for TCR signalling.Nat Rev Immunol 2003;3:939-951[PMID:14647476]
53 Schwartz RH.Costimulation of T lymphocytes:the role of CD28,CTLA-4,and B7/BB1 in interleukin-2 production and immunotherapy.Cell 1992;71:1065-1068[PMID:1335362]
54 Lanzavecchia A.Mechanisms of antigen uptake for presentation.Curr Opin Immunol 1996;8:348-354[PMID:8794000]
55 Grabbe S,Beissert S,Schwarz T,Granstein RD.Dendritic cells as initiators of tumor immune responses:a possible strategy for tumor immunotherapy?Immunol Today 1995;16:117-121[PMID:7718082]
56 Ermann J,Fathman CG.Costimulatory signals controlling regulatory T cells.Proc Natl Acad Sci USA 2003;100:15292-15293[PMID:14676329]
57 Bear AS,Cruz CR,Foster AE.T cells as vehicles for cancer vaccination.J Biomed Biotechnol 2011;2011:417403[PMID:22131805 DOI:10.1155/2011/417403]
58 Zinkernagel RM,Ehl S,Aichele P,Oehen S,Kündig T,Hengartner H.Antigen localisation regulates immune responses in a dose-and time-dependent fashion:a geographical view of immune reactivity.Immunol Rev 1997;156:199-209[PMID:9176709]
59 Hogarth PM,Pietersz GA.Fc receptor-targeted therapies for the treatment of inflammation,cancer and beyond.Nat Rev Drug Discov 2012;11:311-331[PMID:22460124 DOI:10.1038/nrd2909]
60 Kohrt HE,Houot R,Marabelle A,Cho HJ,Osman K,Goldstein M,Levy R,Brody J.Combination strategies to enhance antitumor ADCC.Immunotherapy 2012;4:511-527[PMID:22642334 DOI:10 .2217/imt.12.38]
61 Fanger NA,Wardwell K,Shen L,Tedder TF,Guyre PM.Type I(CD64)and type II(CD32)Fc gamma receptor-mediated phagocytosis by human blood dendritic cells.J Immunol 1996;157:541-548[PMID:8752900]
62 Abdel-Motal UM,Wigglesworth K,Galili U.Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.Cancer Immunol Immunother 2009;58:1545-1556[PMID:19184002 DOI:10 .1007/s00262-009-0662-2]
63 Abdel-Motal UM,Wigglesworth K,Galili U.Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.Vaccine 2009;27:3072-3082[PMID:19428921 DOI:10.1016/j.vaccine.2009.03.019]
64 Deguchi T,Tanemura M,Miyoshi E,Nagano H,Machida T,Ohmura Y,Kobayashi S,Marubashi S,Eguchi H,Takeda Y,Ito T,Mori M,Doki Y,Sawa Y.Increased immunogenicity of tumor-associated antigen,mucin 1,engineered to express alphagal epitopes:a novel approach to immunotherapy in pancreatic cancer.Cancer Res 2010;70:5259-5269[PMID:20530670 DOI:10 .1158/0008-5472.CAN-09-4313]
65 Wang Z,Li Y,Ahmad A,Banerjee S,Azmi AS,Kong D,Sarkar FH.Pancreatic cancer:understanding and overcoming chemoresistance.Nat Rev Gastroenterol Hepatol 2011;8:27-33[PMID:21102532 DOI:10.1038/nrgastro.2010.188]
66 Li C,Heidt DG,Dalerba P,Burant CF,Zhang L,Adsay V,Wicha M,Clarke MF,Simeone DM.Identification of pancreatic cancer stem cells.Cancer Res 2007;67:1030-1037[PMID:17283135]
67 Terao N,Takamatsu S,Minehira T,Sobajima T,Nakayama K,Kamada Y,Miyoshi E.Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.World J Gastroenterol 2015;21:3876-3887[PMID:25852272 DOI:10 .3748/wjg.v21.i13.3876]
68 Yin T,Shi P,Gou S,Shen Q,Wang C.Dendritic cells loaded with pancreatic Cancer Stem Cells(CSCs)lysates induce antitumor immune killing effect in vitro.PLo S One 2014;9:e114581[PMID:25521461 DOI:10.1371/journal.pone.0114581]
69 Hou YC,Chao YJ,Tung HL,Wang HC,Shan YS.Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.Cancer 2014;120:2766-2777[PMID:24839953 DOI:10.1002/cncr.28774]
70 Tanida T,Tanemura M,Miyoshi E,Nagano H,Furukawa K,Nonaka Y,Akita H,Hama N,Wada H,Kawamoto K,Kobayashi S,Eguchi H,Mori M,Doki Y.Pancreatic cancer immunotherapy using a tumor lysate vaccine,engineered to expressα-gal epitopes,targets pancreatic cancer stem cells.Int J Oncol 2015;46:78-90[PMID:25354268 DOI:10.3892/ijo.2014.2717]
2 Cress RD,Yin D,Clarke L,Bold R,Holly EA.Survival among patients with adenocarcinoma of the pancreas:a population-based study(United States).Cancer Causes Control 2006;17:403-409[PMID:16596292]
3 Winter JM,Cameron JL,Campbell KA,Arnold MA,Chang DC,Coleman J,Hodgin MB,Sauter PK,Hruban RH,Riall TS,Schulick RD,Choti MA,Lillemoe KD,Yeo CJ.1423pancreaticoduodenectomies for pancreatic cancer:A singleinstitution experience.J Gastrointest Surg 2006;10:1199-210;discussion 1210-1[PMID:17114007]
4 Garcea G,Dennison AR,Pattenden CJ,Neal CP,Sutton CD,Berry DP.Survival following curative resection for pancreatic ductal adenocarcinoma.A systematic review of the literature.JOP2008;9:99-132[PMID:18326920]
5 Roy R,Maraveyas A.Chemoradiation in pancreatic adenocarcinoma:a literature review.Oncologist 2010;15:259-269[PMID:20203172 DOI:10.1634/theoncologist.2009-0272]
6 Conroy T,Desseigne F,Ychou M,BouchéO,Guimbaud R,Bécouarn Y,Adenis A,Raoul JL,Gourgou-Bourgade S,de la Fouchardière C,Bennouna J,Bachet JB,Khemissa-Akouz F,Péré-VergéD,Delbaldo C,Assenat E,Chauffert B,Michel P,MontotoGrillot C,Ducreux M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med 2011;364:1817-1825[PMID:21561347 DOI:10.1056/NEJMoa1011923]
7 Oettle H,Post S,Neuhaus P,Gellert K,Langrehr J,Ridwelski K,Schramm H,Fahlke J,Zuelke C,Burkart C,Gutberlet K,Kettner E,Schmalenberg H,Weigang-Koehler K,Bechstein WO,Niedergethmann M,Schmidt-Wolf I,Roll L,Doerken B,Riess H.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:a randomized controlled trial.JAMA 2007;297:267-277[PMID:17227978]
8 Feig C,Gopinathan A,Neesse A,Chan DS,Cook N,Tuveson DA.The pancreas cancer microenvironment.Clin Cancer Res2012;18:4266-4276[PMID:22896693 DOI:10.1158/1078-0432.CCR-11-3114]
9 Mantovani A,Allavena P,Sica A,Balkwill F.Cancer-related inflammation.Nature 2008;454:436-444[PMID:18650914 DOI:10 .1038/nature07205]
10 Sideras K,Braat H,Kwekkeboom J,van Eijck CH,Peppelenbosch MP,Sleijfer S,Bruno M.Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.Cancer Treat Rev 2014;40:513-522[PMID:24315741 DOI:10 .1016/j.ctrv.2013.11.005]
11 Olive KP,Jacobetz MA,Davidson CJ,Gopinathan A,Mc Intyre D,Honess D,Madhu B,Goldgraben MA,Caldwell ME,Allard D,Frese KK,Denicola G,Feig C,Combs C,Winter SP,IrelandZecchini H,Reichelt S,Howat WJ,Chang A,Dhara M,Wang L,Rückert F,Grützmann R,Pilarsky C,Izeradjene K,Hingorani SR,Huang P,Davies SE,Plunkett W,Egorin M,Hruban RH,Whitebread N,Mc Govern K,Adams J,Iacobuzio-Donahue C,Griffiths J,Tuveson DA.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science 2009;324:1457-1461[PMID:19460966 DOI:10 .1126/science.1171362]
12 Galili U.Anti-Gal:an abundant human natural antibody of multiple pathogeneses and clinical benefits.Immunology 2013;140:1-11[PMID:23578170 DOI:10.1111/imm.12110]
13 Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin 2011;61:69-90[PMID:21296855 DOI:10.3322/caac.20107]
14 Bakkevold KE,Kambestad B.Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater--the prognostic factors influencing the long-term results.A prospective multicentre study.Eur J Surg Oncol 1993;19:147-161[PMID:7684003]
15 Riall TS,Cameron JL,Lillemoe KD,Winter JM,Campbell KA,Hruban RH,Chang D,Yeo CJ.Resected periampullary adenocarcinoma:5-year survivors and their 6-to 10-year followup.Surgery 2006;140:764-772[PMID:17084719]
16 Burris HA,Moore MJ,Andersen J,Green MR,Rothenberg ML,Modiano MR,Cripps MC,Portenoy RK,Storniolo AM,Tarassoff P,Nelson R,Dorr FA,Stephens CD,Von Hoff DD.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial.J Clin Oncol 1997;15:2403-2413[PMID:9196156]
17 Eguchi H,Nagano H,Tanemura M,Takeda Y,Marubashi S,Kobayashi S,Kawamoto K,Wada H,Hama N,Akita H,Mori M,Doki Y.Preoperative chemoradiotherapy,surgery and adjuvant therapy for resectable pancreatic cancer.Hepatogastroenterology2013;60:904-911[PMID:23321032 DOI:10.5754/hge12974]
18 Evans DB,Varadhachary GR,Crane CH,Sun CC,Lee JE,Pisters PW,Vauthey JN,Wang H,Cleary KR,Staerkel GA,Charnsangavej C,L a n o E A,H o L,L e n z i R,A b b r u z z e s e J L,Wo l ff R A.Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.J Clin Oncol2008;26:3496-3502[PMID:18640930 DOI:10.1200/JCO.2007]
19 Ohigashi H,Ishikawa O,Eguchi H,Takahashi H,Gotoh K,Yamada T,Yano M,Nakaizumi A,Uehara H,Tomita Y,Nishiyama K.Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine,concurrent three-dimensional conformal radiation,surgery,and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.Ann Surg 2009;250:88-95[PMID:19561477 DOI:10.1097/SLA.0b013e3181ad65cc]
20 Wedén S,Klemp M,Gladhaug IP,M?ller M,Eriksen JA,Gaudernack G,Buanes T.Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras.Int J Cancer 2011;128:1120-1128[PMID:20473937 DOI:10 .1002/ijc.25449]
21 Shakhar G,Ben-Eliyahu S.Potential prophylactic measures against postoperative immunosuppression:could they reduce recurrence rates in oncological patients?Ann Surg Oncol 2003;10:972-992[PMID:14527919]
22 Weighardt H,Heidecke CD,Emmanuilidis K,Maier S,Bartels H,Siewert JR,Holzmann B.Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production.Surgery 2000;127:309-315[PMID:10715987]
23 Zou W.Immunosuppressive networks in the tumour environment and their therapeutic relevance.Nat Rev Cancer 2005;5:263-274[PMID:15776005]
24 Kraman M,Bambrough PJ,Arnold JN,Roberts EW,Magiera L,Jones JO,Gopinathan A,Tuveson DA,Fearon DT.Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.Science 2010;330:827-830[PMID:21051638 DOI:10.1126/science.1195300]
25 Erez N,Truitt M,Olson P,Arron ST,Hanahan D.CancerAssociated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappa BDependent Manner.Cancer Cell 2010;17:135-147[PMID:20138012 DOI:10.1016/j.ccr.2009.12.041]
26 Shi M,Yu DH,Chen Y,Zhao CY,Zhang J,Liu QH,Ni CR,Zhu MH.Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.World J Gastroenterol 2012;18:840-846[PMID:22371645 DOI:10 .3748/wjg.v18.i8.840]
27 Ostrand-Rosenberg S.Myeloid-derived suppressor cells:more mechanisms for inhibiting antitumor immunity.Cancer Immunol Immunother 2010;59:1593-1600[PMID:20414655 DOI:10 .1007/s00262-010-0855-8]
28 Gabitass RF,Annels NE,Stocken DD,Pandha HA,Middleton GW.Elevated myeloid-derived suppressor cells in pancreatic,esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.Cancer Immunol Immunother 2011;60:1419-1430[PMID:21644036 DOI:10.1007/s00262-011-1028-0]
29 Zhao F,Obermann S,von Wasielewski R,Haile L,Manns MP,Korangy F,Greten TF.Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.Immunology 2009;128:141-149[PMID:19689743 DOI:10.1111/j.1365-2567.2009.03105.x]
30 Esposito I,Menicagli M,Funel N,Bergmann F,Boggi U,Mosca F,Bevilacqua G,Campani D.Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma.J Clin Pathol 2004;57:630-636[PMID:15166270]
31 Kurahara H,Shinchi H,Mataki Y,Maemura K,Noma H,Kubo F,Sakoda M,Ueno S,Natsugoe S,Takao S.Significance of M2-polarized tumor-associated macrophage in pancreatic cancer.J Surg Res 2011;167:e211-e219[PMID:19765725 DOI:10.1016/j.jss.2009.05.026]
32 Ikemoto T,Yamaguchi T,Morine Y,Imura S,Soejima Y,Fujii M,Maekawa Y,Yasutomo K,Shimada M.Clinical roles of increased populations of Foxp3+CD4+T cells in peripheral blood from advanced pancreatic cancer patients.Pancreas 2006;33:386-390[PMID:17079944]
33 Hiraoka N,Onozato K,Kosuge T,Hirohashi S.Prevalence of FOXP3+regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.Clin Cancer Res 2006;12:5423-5434[PMID:17000676]
34 Yamamoto T,Yanagimoto H,Satoi S,Toyokawa H,Hirooka S,Yamaki S,Yui R,Yamao J,Kim S,Kwon AH.Circulating CD4+CD25+regulatory T cells in patients with pancreatic cancer.Pancreas 2012;41:409-415[PMID:22158072 DOI:10.1097/MPA.0b013e3182373a66]
35 Galili U.The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.Immunol Cell Biol 2005;83:674-686[PMID:16266320]
36 Macher BA,Galili U.The Galalpha1,3Galbeta1,4Glc NAc-R(alpha-Gal)epitope:a carbohydrate of unique evolution and clinical relevance.Biochim Biophys Acta 2008;1780:75-88[PMID:18047841]
37 Kearns-Jonker M,Swensson J,Ghiuzeli C,Chu W,Osame Y,Starnes V,Cramer DV.The human antibody response to porcine xenoantigens is encoded by IGHV3-11 and IGHV3-74 Ig VH germline progenitors.J Immunol 1999;163:4399-4412[PMID:10510381]
38 Eto T,Ichikawa Y,Nishimura K,Ando S,Yamakawa T.Chemistry of lipid of the posthemyolytic residue or stroma of erythrocytes.XVI.Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes of rabbit.J Biochem 1968;64:205-213[PMID:4304380]
39 Stellner K,Saito H,Hakomori SI.Determination of aminosugar linkages in glycolipids by methylation.Aminosugar linkages of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen.Arch Biochem Biophys 1973;155:464-472[PMID:4735853]
40 Galili U.Discovery of the natural anti-Gal antibody and its past and future relevance to medicine.Xenotransplantation 2013;20:138-147[PMID:23577774 DOI:10.1111/xen.12034]
41 Tanemura M,Yin D,Chong AS,Galili U.Differential immune responses to alpha-gal epitopes on xenografts and allografts:implications for accommodation in xenotransplantation.J Clin Invest 2000;105:301-310[PMID:10675356]
42 Ekser B,Ezzelarab M,Hara H,van der Windt DJ,Wijkstrom M,Bottino R,Trucco M,Cooper DK.Clinical xenotransplantation:the next medical revolution?Lancet 2012;379:672-683[PMID:22019026 DOI:10.1016/S0140-6736(11)61091-X]
43 Tisato V,Cozzi E.Xenotransplantation:an overview of the field.Methods Mol Biol 2012;885:1-16[PMID:22565986 DOI:10.1007 /978-1-61779-845-0_1]
44 Groth CG,Korsgren O,Tibell A,Tollemar J,M?ller E,Bolinder J,Ostman J,Reinholt FP,Hellerstr?m C,Andersson A.Transplantation of porcine fetal pancreas to diabetic patients.Lancet 1994;344:1402-1404[PMID:7968077]
45 Lai L,Kolber-Simonds D,Park KW,Cheong HT,Greenstein JL,Im GS,Samuel M,Bonk A,Rieke A,Day BN,Murphy CN,Carter DB,Hawley RJ,Prather RS.Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.Science 2002;295:1089-1092[PMID:11778012]
46 Phelps CJ,Koike C,Vaught TD,Boone J,Wells KD,Chen SH,Ball S,Specht SM,Polejaeva IA,Monahan JA,Jobst PM,Sharma SB,Lamborn AE,Garst AS,Moore M,Demetris AJ,Rudert WA,Bottino R,Bertera S,Trucco M,Starzl TE,Dai Y,Ayares DL.Production of alpha 1,3-galactosyltransferase-deficient pigs.Science 2003;299:411-414[PMID:12493821]
47 Yamada K,Yazawa K,Shimizu A,Iwanaga T,Hisashi Y,Nuhn M,O’Malley P,Nobori S,Vagefi PA,Patience C,Fishman J,Cooper DK,Hawley RJ,Greenstein J,Schuurman HJ,Awwad M,Sykes M,Sachs DH.Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase geneknockout donors and the cotransplantation of vascularized thymic tissue.Nat Med 2005;11:32-34[PMID:15619627]
48 Kuwaki K,Tseng YL,Dor FJ,Shimizu A,Houser SL,Sanderson TM,Lancos CJ,Prabharasuth DD,Cheng J,Moran K,Hisashi Y,Mueller N,Yamada K,Greenstein JL,Hawley RJ,Patience C,Awwad M,Fishman JA,Robson SC,Schuurman HJ,Sachs DH,Cooper DK.Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors:initial experience.Nat Med 2005;11:29-31[PMID:15619628]
49 Saito H,Dubsky P,Dantin C,Finn OJ,Banchereau J,Palucka AK.Cross-priming of cyclin B1,MUC-1 and survivin-specific CD8+T cells by dendritic cells loaded with killed allogeneic breast cancer cells.Breast Cancer Res 2006;8:R65[PMID:17129372]
50 Thomas AM,Santarsiero LM,Lutz ER,Armstrong TD,Chen YC,Huang LQ,Laheru DA,Goggins M,Hruban RH,Jaffee EM.Mesothelin-specific CD8(+)T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.J Exp Med 2004;200:297-306[PMID:15289501]
51 Jaffee EM,Hruban RH,Biedrzycki B,Laheru D,Schepers K,Sauter PR,Goemann M,Coleman J,Grochow L,Donehower RC,Lillemoe KD,O’Reilly S,Abrams RA,Pardoll DM,Cameron JL,Yeo CJ.Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer:a phase I trial of safety and immune activation.J Clin Oncol 2001;19:145-156[PMID:11134207]
52 Acuto O,Michel F.CD28-mediated co-stimulation:a quantitative support for TCR signalling.Nat Rev Immunol 2003;3:939-951[PMID:14647476]
53 Schwartz RH.Costimulation of T lymphocytes:the role of CD28,CTLA-4,and B7/BB1 in interleukin-2 production and immunotherapy.Cell 1992;71:1065-1068[PMID:1335362]
54 Lanzavecchia A.Mechanisms of antigen uptake for presentation.Curr Opin Immunol 1996;8:348-354[PMID:8794000]
55 Grabbe S,Beissert S,Schwarz T,Granstein RD.Dendritic cells as initiators of tumor immune responses:a possible strategy for tumor immunotherapy?Immunol Today 1995;16:117-121[PMID:7718082]
56 Ermann J,Fathman CG.Costimulatory signals controlling regulatory T cells.Proc Natl Acad Sci USA 2003;100:15292-15293[PMID:14676329]
57 Bear AS,Cruz CR,Foster AE.T cells as vehicles for cancer vaccination.J Biomed Biotechnol 2011;2011:417403[PMID:22131805 DOI:10.1155/2011/417403]
58 Zinkernagel RM,Ehl S,Aichele P,Oehen S,Kündig T,Hengartner H.Antigen localisation regulates immune responses in a dose-and time-dependent fashion:a geographical view of immune reactivity.Immunol Rev 1997;156:199-209[PMID:9176709]
59 Hogarth PM,Pietersz GA.Fc receptor-targeted therapies for the treatment of inflammation,cancer and beyond.Nat Rev Drug Discov 2012;11:311-331[PMID:22460124 DOI:10.1038/nrd2909]
60 Kohrt HE,Houot R,Marabelle A,Cho HJ,Osman K,Goldstein M,Levy R,Brody J.Combination strategies to enhance antitumor ADCC.Immunotherapy 2012;4:511-527[PMID:22642334 DOI:10 .2217/imt.12.38]
61 Fanger NA,Wardwell K,Shen L,Tedder TF,Guyre PM.Type I(CD64)and type II(CD32)Fc gamma receptor-mediated phagocytosis by human blood dendritic cells.J Immunol 1996;157:541-548[PMID:8752900]
62 Abdel-Motal UM,Wigglesworth K,Galili U.Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity.Cancer Immunol Immunother 2009;58:1545-1556[PMID:19184002 DOI:10 .1007/s00262-009-0662-2]
63 Abdel-Motal UM,Wigglesworth K,Galili U.Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.Vaccine 2009;27:3072-3082[PMID:19428921 DOI:10.1016/j.vaccine.2009.03.019]
64 Deguchi T,Tanemura M,Miyoshi E,Nagano H,Machida T,Ohmura Y,Kobayashi S,Marubashi S,Eguchi H,Takeda Y,Ito T,Mori M,Doki Y,Sawa Y.Increased immunogenicity of tumor-associated antigen,mucin 1,engineered to express alphagal epitopes:a novel approach to immunotherapy in pancreatic cancer.Cancer Res 2010;70:5259-5269[PMID:20530670 DOI:10 .1158/0008-5472.CAN-09-4313]
65 Wang Z,Li Y,Ahmad A,Banerjee S,Azmi AS,Kong D,Sarkar FH.Pancreatic cancer:understanding and overcoming chemoresistance.Nat Rev Gastroenterol Hepatol 2011;8:27-33[PMID:21102532 DOI:10.1038/nrgastro.2010.188]
66 Li C,Heidt DG,Dalerba P,Burant CF,Zhang L,Adsay V,Wicha M,Clarke MF,Simeone DM.Identification of pancreatic cancer stem cells.Cancer Res 2007;67:1030-1037[PMID:17283135]
67 Terao N,Takamatsu S,Minehira T,Sobajima T,Nakayama K,Kamada Y,Miyoshi E.Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.World J Gastroenterol 2015;21:3876-3887[PMID:25852272 DOI:10 .3748/wjg.v21.i13.3876]
68 Yin T,Shi P,Gou S,Shen Q,Wang C.Dendritic cells loaded with pancreatic Cancer Stem Cells(CSCs)lysates induce antitumor immune killing effect in vitro.PLo S One 2014;9:e114581[PMID:25521461 DOI:10.1371/journal.pone.0114581]
69 Hou YC,Chao YJ,Tung HL,Wang HC,Shan YS.Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.Cancer 2014;120:2766-2777[PMID:24839953 DOI:10.1002/cncr.28774]
70 Tanida T,Tanemura M,Miyoshi E,Nagano H,Furukawa K,Nonaka Y,Akita H,Hama N,Wada H,Kawamoto K,Kobayashi S,Eguchi H,Mori M,Doki Y.Pancreatic cancer immunotherapy using a tumor lysate vaccine,engineered to expressα-gal epitopes,targets pancreatic cancer stem cells.Int J Oncol 2015;46:78-90[PMID:25354268 DOI:10.3892/ijo.2014.2717]